Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension

Publisher： John Wiley & Sons Inc

E-ISSN： 1751-7176|20|2|351-355

ISSN： 1524-6175

Source： The Journal of Clinical Hypertension, Vol.20, Iss.2, 2018-02, pp. : 351-355

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double‐blind, 8‐week study

By  

The Journal of Clinical Hypertension, Vol. 20, Iss. 1, 2018-01 ,pp. : 150-158

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sacubitril/valsartan instead of renin‐angiotensin system inhibition alone: A step forward in resistant hypertension

By  

The Journal of Clinical Hypertension, Vol. 20, Iss. 1, 2018-01 ,pp. : 65-68

John Wiley & Sons Inc

Access to resources Recommend Favorite

Additivity of nebivolol/valsartan single‐pill combinations versus other single‐pill combinations for hypertension

By  

The Journal of Clinical Hypertension, Vol. 20, Iss. 1, 2018-01 ,pp. : 143-149

John Wiley & Sons Inc

Access to resources Recommend Favorite

Independent predictors of effective blood pressure control in patients with hypertension on drug treatment in Brazil

By  

The Journal of Clinical Hypertension, Vol. 20, Iss. 1, 2018-01 ,pp. : 125-132

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prevalence, Awareness, Treatment, and Control of Hypertension in Lebanon

By  

The Journal of Clinical Hypertension, Vol. 17, Iss. 5, 2015-05 ,pp. : 381-388

John Wiley & Sons Inc

Access to resources Recommend Favorite